Transparency in Clinical Evidence Sources

Study transparency is key to pharmaceutical data. The ability to easily access the clinical evidence used to make reimbursement decisions could potentially save time and minimize redundancy. However, the availability of this information in a consistent and accessible format is a challenge.

This webinar examines the behavior of influential HTA agencies, matching unique clinical trial outcomes with HTA reviews to see how much information is shared. The presentation features a panel discussion on the impact of unstructured data on market access and proven techniques to manage this data.